Rami Rahal, Ph.D.
Dr. Rami Rahal is responsible for investment identification and due diligence for MPM BioImpact Capital.
Prior to joining MPM BioImpact, Rami spent the majority of his career in drug discovery prosecuting multiple target classes for both precision oncology and immunotherapy. Most recently, he was a Senior Director of Cancer Biology at Scorpion Therapeutics where he joined as the first biologist and played pivotal roles in expanding the biology drug discovery team, research infrastructure, and early portfolio. Before joining Scorpion Therapeutics, Rami was at KSQ Therapeutics, where he led multiple small molecule drug discovery programs for novel IO targets and helped build an integrative IO drug discovery strategy. Rami began his career in biotech at Blueprint Medicines where he served as the lead biologist for the RET inhibitor program (BLU-667/Pralsetinib) from early optimization into Phase 1. Pralsetinib is now an FDA approved medicine (Gavreto) for RET-driven metastatic NSCLC and medullary thyroid cancer.
Rami earned his PhD in Genetics from MIT and conducted postdoctoral fellowships at Harvard Medical School and the Novartis Institutes of Biomedical Research (NIBR). At NIBR, he leveraged pharmacological and genomic profiling to identify new treatment strategies for mantle cell lymphoma and characterized novel synthetic lethal cancer vulnerabilities. His work has been highlighted in Cancer Cell, Cancer Discovery, and Nature Reviews Cancer.